South Korea’s PharmaResearch launched its Rejuran Cosmetics skincare line across all 148 Sephora Canada stores on Sept. 1.
The nationwide rollout places eight product formulations, including its Turnover Ampoule and Dual Effect Ampoule, into Canadian retail stores alongside Sephora’s online channel.
Featured on Sephora Canada’s Skincare Next Big Thing Wall, the collection relies on c-PDRN, a cosmetic ingredient purified from wild salmon DNA. PharmaResearch developed the compound from the polynucleotide technologies it uses in its injectable aesthetic skin boosters sold across more than 50 countries.
Translating Clinical Injectables to Prestige Shelves
The Canadian retail launch extends a clear playbook: converting medical aesthetic brand equity into mass prestige topical products. Consumers familiar with professional clinic procedures in Asia are increasingly seeking the same bio-active ingredients in daily skincare regimens.
“Through a tailored omnichannel strategy, we aim to build meaningful connections with Canadian consumers and strengthen our market presence,” said Jooyeon Song, Head of Cosmetics at PharmaResearch USA.
Margin Pressures and Shelf Competition
Derma-cosmetic brands derived from Asian pharmaceuticals face a different commercial environment in North American retail compared to domestic clinic networks. Prestige beauty retailers demand heavy promotional support, co-op marketing fees, and dedicated floor space allocations that can compress wholesale margins if inventory turns slow down.
Competition on the derma-skincare wall is intense. Rejuran must defend shelf share against entrenched clinical lines and lower-priced Korean skincare competitors already commanding established followings across Canadian cities.
US Manufacturing Shapes North American Strategy
In July, PharmaResearch agreed to acquire California contract manufacturer Cosmetic Group USA to secure domestic production capacity and stabilize supply lines across the Americas. That transaction followed the brand’s US retail debut in Sephora stores earlier in the year and coincided with a concurrent retail entry into Sephora Singapore.
PharmaResearch will now focus on closing the integration of Cosmetic Group USA’s production facilities to supply North American retail channels directly and cut transpacific freight lead times from its Gangneung base.
